These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11140434)

  • 1. Bioavailability of orally administered micronised fluticasone propionate.
    Falcoz C; Oliver R; McDowall JE; Ventresca P; Bye A; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():9-15. PubMed ID: 11140434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers.
    Mackie AE; McDowall JE; Falcoz C; Ventresca P; Bye A; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():23-30. PubMed ID: 11140430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.
    Mackie AE; Bye A
    Clin Pharmacokinet; 2000; 39 Suppl 1():47-54. PubMed ID: 11140433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
    Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
    Möllmann H; Wagner M; Krishnaswami S; Dimova H; Tang Y; Falcoz C; Daley-Yates PT; Krieg M; Stöckmann R; Barth J; Lawlor C; Möllmann AC; Derendorf H; Hochhaus G
    J Clin Pharmacol; 2001 Dec; 41(12):1329-38. PubMed ID: 11762560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers.
    Brindley C; Falcoz C; Mackie AE; Bye A
    Clin Pharmacokinet; 2000; 39 Suppl 1():1-8. PubMed ID: 11140428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma.
    Falcoz C; Horton J; Mackie AE; Harding SM; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():31-7. PubMed ID: 11140431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate.
    Rohatagi S; Bye A; Falcoz C; Mackie AE; Meibohm B; Möllmann H; Derendorf H
    J Clin Pharmacol; 1996 Oct; 36(10):938-41. PubMed ID: 8930781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers.
    Dempsey OJ; Humphreys M; Coutie WJ; Lipworth BJ
    Eur J Clin Pharmacol; 2001 Nov; 57(9):637-41. PubMed ID: 11791892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma.
    Daley-Yates PT; Tournant J; Kunka RL
    Clin Pharmacokinet; 2000; 39 Suppl 1():39-45. PubMed ID: 11140432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.
    Minto C; Li B; Tattam B; Brown K; Seale JP; Donnelly R
    Br J Clin Pharmacol; 2000 Aug; 50(2):116-24. PubMed ID: 10930963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.
    Brutsche MH; Brutsche IC; Munawar M; Langley SJ; Masterson CM; Daley-Yates PT; Brown R; Custovic A; Woodcock A
    Lancet; 2000 Aug; 356(9229):556-61. PubMed ID: 10950233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.
    Thorsson L; Dahlström K; Edsbäcker S; Källén A; Paulson J; Wirén JE
    Br J Clin Pharmacol; 1997 Feb; 43(2):155-61. PubMed ID: 9131947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers.
    Wales D; Makker H; Kane J; McDowell P; O'Driscoll BR
    Chest; 1999 May; 115(5):1278-84. PubMed ID: 10334140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.
    Möllmann H; Wagner M; Meibohm B; Hochhaus G; Barth J; Stöckmann R; Krieg M; Weisser H; Falcoz C; Derendorf H
    Eur J Clin Pharmacol; 1998 Feb; 53(6):459-67. PubMed ID: 9551705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.
    Grahnén A; Eckernäs SA; Brundin RM; Ling-Andersson A
    Br J Clin Pharmacol; 1994 Dec; 38(6):521-5. PubMed ID: 7888290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
    Lanz MJ; Eisenlohr C; Llabre MM; Toledo Y; Lanz MA
    Ann Allergy Asthma Immunol; 2001 Oct; 87(4):283-8. PubMed ID: 11686419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
    Lee DK; Fardon TC; Bates CE; Haggart K; McFarlane LC; Lipworth BJ
    Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.
    Singh SD; Whale C; Houghton N; Daley-Yates P; Kirby SM; Woodcock AA
    Br J Clin Pharmacol; 2003 Apr; 55(4):375-81. PubMed ID: 12680886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.